Abstract

A growing amount of evidence suggests that a disturbance of immunological function is of importance in the pathogenesis of multiple sclerosis. This is reflected in the drugs used to slow progression and to treat relapses. Immunosuppressive drugs such as azathioprine, cyclophosphamide and cyclosporin might have some potential to slow down progression of multiple sclerosis, but their use is limited by potentially serious adverse effects. Recently, it was shown that interferon-β-1b can diminish the exacerbation rate in multiple sclerosis without leading to unacceptable adverse effects. Nevertheless, symptomatic treatment remains of crucial importance in the management of multiple sclerosis patients. Spasticity, depression, fatigue and urinary, paroxysmal and sensory symptoms can all be alleviated to some extent with pharmacological interventions, although rehabilitation procedures and psychosocial consultations are no less important. Further therapeutic approaches to multiple sclerosis will be directed at either the specificity of the immune response or the grade of activation of the immune response. Magnetic resonance imaging techniques will play an important role in the evaluation of efficacy of new therapeutic agents.

Original languageEnglish
Pages (from-to)200-212
Number of pages13
JournalDrugs
Volume49
Issue number2
DOIs
Publication statusPublished - 1 Jan 1995

Cite this

@article{2e5dc1f91a0e434da69f70e6423b0706,
title = "Multiple Sclerosis Therapy: A Practical Guide",
abstract = "A growing amount of evidence suggests that a disturbance of immunological function is of importance in the pathogenesis of multiple sclerosis. This is reflected in the drugs used to slow progression and to treat relapses. Immunosuppressive drugs such as azathioprine, cyclophosphamide and cyclosporin might have some potential to slow down progression of multiple sclerosis, but their use is limited by potentially serious adverse effects. Recently, it was shown that interferon-β-1b can diminish the exacerbation rate in multiple sclerosis without leading to unacceptable adverse effects. Nevertheless, symptomatic treatment remains of crucial importance in the management of multiple sclerosis patients. Spasticity, depression, fatigue and urinary, paroxysmal and sensory symptoms can all be alleviated to some extent with pharmacological interventions, although rehabilitation procedures and psychosocial consultations are no less important. Further therapeutic approaches to multiple sclerosis will be directed at either the specificity of the immune response or the grade of activation of the immune response. Magnetic resonance imaging techniques will play an important role in the evaluation of efficacy of new therapeutic agents.",
author = "{van Oosten}, {Bob W.} and Luc Truyen and Frederik Barkhof and Polman, {Chris H.}",
year = "1995",
month = "1",
day = "1",
doi = "10.2165/00003495-199549020-00005",
language = "English",
volume = "49",
pages = "200--212",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "2",

}

Multiple Sclerosis Therapy : A Practical Guide. / van Oosten, Bob W.; Truyen, Luc; Barkhof, Frederik; Polman, Chris H.

In: Drugs, Vol. 49, No. 2, 01.01.1995, p. 200-212.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Multiple Sclerosis Therapy

T2 - A Practical Guide

AU - van Oosten, Bob W.

AU - Truyen, Luc

AU - Barkhof, Frederik

AU - Polman, Chris H.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A growing amount of evidence suggests that a disturbance of immunological function is of importance in the pathogenesis of multiple sclerosis. This is reflected in the drugs used to slow progression and to treat relapses. Immunosuppressive drugs such as azathioprine, cyclophosphamide and cyclosporin might have some potential to slow down progression of multiple sclerosis, but their use is limited by potentially serious adverse effects. Recently, it was shown that interferon-β-1b can diminish the exacerbation rate in multiple sclerosis without leading to unacceptable adverse effects. Nevertheless, symptomatic treatment remains of crucial importance in the management of multiple sclerosis patients. Spasticity, depression, fatigue and urinary, paroxysmal and sensory symptoms can all be alleviated to some extent with pharmacological interventions, although rehabilitation procedures and psychosocial consultations are no less important. Further therapeutic approaches to multiple sclerosis will be directed at either the specificity of the immune response or the grade of activation of the immune response. Magnetic resonance imaging techniques will play an important role in the evaluation of efficacy of new therapeutic agents.

AB - A growing amount of evidence suggests that a disturbance of immunological function is of importance in the pathogenesis of multiple sclerosis. This is reflected in the drugs used to slow progression and to treat relapses. Immunosuppressive drugs such as azathioprine, cyclophosphamide and cyclosporin might have some potential to slow down progression of multiple sclerosis, but their use is limited by potentially serious adverse effects. Recently, it was shown that interferon-β-1b can diminish the exacerbation rate in multiple sclerosis without leading to unacceptable adverse effects. Nevertheless, symptomatic treatment remains of crucial importance in the management of multiple sclerosis patients. Spasticity, depression, fatigue and urinary, paroxysmal and sensory symptoms can all be alleviated to some extent with pharmacological interventions, although rehabilitation procedures and psychosocial consultations are no less important. Further therapeutic approaches to multiple sclerosis will be directed at either the specificity of the immune response or the grade of activation of the immune response. Magnetic resonance imaging techniques will play an important role in the evaluation of efficacy of new therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0028982907&partnerID=8YFLogxK

U2 - 10.2165/00003495-199549020-00005

DO - 10.2165/00003495-199549020-00005

M3 - Article

VL - 49

SP - 200

EP - 212

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 2

ER -